Trials / Completed
CompletedNCT00564681
Study to Evaluate Safety, Efficacy of Botulinum Toxin Type A in Patients With Cervical Dystonia
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 242 (actual)
- Sponsor
- Allergan · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Study is to investigate the use of the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) scale in a cervical dystonia population treated with botulinum toxin type A, and placebo.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | botulinum toxin type A | Intramuscular injections into the affected muscles. Maximum dose of 360 units. Subjects may receive up to three treatments. |
| BIOLOGICAL | botulinum toxin type A Formulation 2 | Intramuscular injections into the affected muscles. Maximum dose of 360 units. Subjects may receive up to three treatments. |
| DRUG | Normal Saline | Intramuscular injections of placebo (normal saline) into the affected muscles for treatment cycle 1. |
Timeline
- Start date
- 2007-12-01
- Primary completion
- 2008-12-01
- Completion
- 2009-12-01
- First posted
- 2007-11-28
- Last updated
- 2016-01-05
- Results posted
- 2012-12-11
Locations
16 sites across 16 countries: United States, Canada, Czechia, Germany, Hungary, India, Philippines, Poland, Russia, Serbia, Singapore, Slovakia, South Africa, Taiwan, Thailand, United Kingdom
Source: ClinicalTrials.gov record NCT00564681. Inclusion in this directory is not an endorsement.